201 related articles for article (PubMed ID: 35183872)
1. Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo.
Bin H; Chen P; Wu M; Wang F; Lin G; Pan S; Liu J; Mu B; Nan J; Huang Q; Li L; Yang S
Eur J Med Chem; 2022 Mar; 232():114187. PubMed ID: 35183872
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
Shao J; Huang L; Lai W; Zou Y; Zhu Q
Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).
Wang LW; Jiang S; Yuan YH; Duan J; Mao ND; Hui Z; Bai R; Xie T; Ye XY
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458687
[TBL] [Abstract][Full Text] [Related]
5. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors.
Chen P; Bin H; Jiao Y; Lin G; Zhang Y; Xia A; Pan Z; Qiao J; Guo Y; Liu J; Zhou Y; Li L
Bioorg Med Chem Lett; 2022 May; 63():128651. PubMed ID: 35245663
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Alfayomy AM; Ashry R; Kansy AG; Sarnow AC; Erdmann F; Schmidt M; Krämer OH; Sippl W
Eur J Med Chem; 2024 Mar; 267():116167. PubMed ID: 38308949
[TBL] [Abstract][Full Text] [Related]
10. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
Yap TA; Tan DSP; Terbuch A; Caldwell R; Guo C; Goh BC; Heong V; Haris NRM; Bashir S; Drew Y; Hong DS; Meric-Bernstam F; Wilkinson G; Hreiki J; Wengner AM; Bladt F; Schlicker A; Ludwig M; Zhou Y; Liu L; Bordia S; Plummer R; Lagkadinou E; de Bono JS
Cancer Discov; 2021 Jan; 11(1):80-91. PubMed ID: 32988960
[TBL] [Abstract][Full Text] [Related]
11. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
Shaik A; Bhakuni R; Kirubakaran S
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
[TBL] [Abstract][Full Text] [Related]
13. Dbf4 is direct downstream target of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint.
Lee AY; Chiba T; Truong LN; Cheng AN; Do J; Cho MJ; Chen L; Wu X
J Biol Chem; 2012 Jan; 287(4):2531-43. PubMed ID: 22123827
[TBL] [Abstract][Full Text] [Related]
14. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases.
Cortez D
J Biol Chem; 2003 Sep; 278(39):37139-45. PubMed ID: 12847089
[TBL] [Abstract][Full Text] [Related]
15. The development of ataxia telangiectasia mutated kinase inhibitors.
Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents.
Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR
J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798
[TBL] [Abstract][Full Text] [Related]
17. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
[TBL] [Abstract][Full Text] [Related]
18. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
19. A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints.
Mu JJ; Wang Y; Luo H; Leng M; Zhang J; Yang T; Besusso D; Jung SY; Qin J
J Biol Chem; 2007 Jun; 282(24):17330-4. PubMed ID: 17478428
[TBL] [Abstract][Full Text] [Related]
20. Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.
Mavroeidi D; Georganta A; Panagiotou E; Syrigos K; Souliotis VL
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
